Understanding the nuances behind why a physician makes a decision regarding an information source when making a clinical decision is key to learning the best way to deliver content that will prompt an engagement.
Generic drugmaker Mylan NV said its manufacturing partner for EpiPen devices had expanded a recall of the life-saving allergy shot in the United States and other markets.
Kaspar the social robot has helped around 170 autistic children in a handful of schools and hospitals over the last 10 years. But with approximately 700,000 people in Britain on the autism spectrum, according to the National Autistic Society, the university wants Kaspar to help more people.
Napo Pharmaceuticals Inc. – a human health company developing and commercializing novel gastrointestinal prescription products from plants used traditionally in rainforest areas – and Jaguar Animal Health Inc. – an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals and high value horses – announced today that they have entered into a definitive merger agreement by unanimous approval by the boards of directors of both companies.
The U.S. FDA granted full approval for Tagrisso (osimertinib) 80-mg once-daily tablets for treating metastatic EGFR T790M mutation-positive NSCLC.
Vencerx Therapeutics announced that Robert Ring will join the company as chief executive officer and Jeffrey Stevenson will join as chairman of the board.
GV has invested in a company called SpyBiotech, which focuses on a so-called “super glue” that combines two parts of the bacteria that causes strep throat.
As biologic medications administered through prefilled syringes continue to supplement and enter new therapeutic areas, more and more patients will need to embark on a learning curve that is possibly unlike any they have experienced prior.
Seattle Genetics announced that Karen Walker will be joining the company as vice president of Global Quality in mid-April 2017. She was formerly vice president Global Head Cell and Gene Therapies Technical Development and Manufacturing at Novartis.
Espero Pharmaceuticals – a commercial-stage cardiovascular pharma company – and Armetheon – a late-clinical stage pharma company developing innovative novel drugs addressing major unmet needs in cardiovascular diseases – plan to merge.
Heartbeat announced that its founder Bill Drummy has stepped down as CEO after 18 years of running the perennially successful healthcare marketing agency.
Merrimack Stockholders Approve Sale of Onivyde and Generic Version of Doxil to Ipsen for Up to $1.025 Billion
Merrimack Pharmaceuticals Inc. announced that the company will sell to Ipsen SA its first commercial product Onivyde and
its generic version of doxorubicin hydrochloride (HCI) liposome injection, which is marketed in the United States as Doxil.
Eleven biotech companies and research teams in Britain and the United States were awarded up to $48 million in funding to speed development of new antibiotics powerful enough to take on the world’s deadliest superbugs.
SSCG Media Group Study Finds “Rule of Three” is Most Effective in Reaching Physicians with Pharma Advertising NEW YORK, March 30, 2017 /PRNewswire/ — How can pharma advertisers best engage physicians? A leading pharma-focused media company went straight to the source to find out that the answer is the “Rule of Three.” Today, […]
An anti-inflammatory drug being developed by Corbus Pharmaceuticals Holdings as an add-on treatment for cystic fibrosis demonstrated promising safety and was well tolerated in a small midstage study, according to data released by the company.
Early in January 2017, Takeda Pharmaceutical acquired Cambridge, Mass.-based Ariad Pharmaceuticals for approximately $5.2 billion. The Boston Business Journal reported that less than half of Ariad’s 300 employees will remain at that company.
Lexington, Mass.-based Agenus announced today that it will reorganize its business and operations, including cutting about 50 jobs.
In the race to get a CAR-T therapeutic to the market, Novartis announced that the U.S. FDA accepted its BLA filing and granted priority review for CTL019.
GlaxoSmithKline’s new CEO Emma Walmsley won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.
Essay Support A lot of students need essay support due to the fact university tasks are usually time consuming. Would you spend some time carrying out analysis for many random essay when you could utilize that extra time to do something diffrent fully?